ATA382484A - Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer - Google Patents

Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer

Info

Publication number
ATA382484A
ATA382484A AT843824A AT382484A ATA382484A AT A382484 A ATA382484 A AT A382484A AT 843824 A AT843824 A AT 843824A AT 382484 A AT382484 A AT 382484A AT A382484 A ATA382484 A AT A382484A
Authority
AT
Austria
Prior art keywords
transistor
switching stage
power
power transistor
transistor switching
Prior art date
Application number
AT843824A
Other languages
English (en)
Other versions
AT394948B (de
Original Assignee
Lowey Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lowey Hans filed Critical Lowey Hans
Publication of ATA382484A publication Critical patent/ATA382484A/de
Application granted granted Critical
Publication of AT394948B publication Critical patent/AT394948B/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0382484A 1983-12-01 1984-11-30 Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer AT394948B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,844 US4680323A (en) 1983-12-01 1983-12-01 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Publications (2)

Publication Number Publication Date
ATA382484A true ATA382484A (de) 1992-01-15
AT394948B AT394948B (de) 1992-07-27

Family

ID=24223083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0382484A AT394948B (de) 1983-12-01 1984-11-30 Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer

Country Status (26)

Country Link
US (1) US4680323A (de)
JP (1) JPS60185728A (de)
KR (1) KR930000046B1 (de)
AT (1) AT394948B (de)
AU (1) AU572571B2 (de)
BE (1) BE901186A (de)
CA (1) CA1229551A (de)
CH (1) CH664970A5 (de)
DE (1) DE3443587C2 (de)
DK (1) DK162511C (de)
EG (1) EG17134A (de)
FI (1) FI82601C (de)
FR (1) FR2555901B1 (de)
GB (1) GB2152940B (de)
HU (1) HU193717B (de)
IE (1) IE58112B1 (de)
IL (1) IL73594A (de)
IT (1) IT1177152B (de)
LU (1) LU85660A1 (de)
MX (1) MX161165A (de)
NL (1) NL193164C (de)
NO (1) NO167002C (de)
NZ (1) NZ210310A (de)
PT (1) PT79427B (de)
SE (1) SE461071B (de)
ZA (1) ZA849373B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
US4783331A (en) * 1987-06-29 1988-11-08 Miles Inc. Method for solubilization of aspartame in effervescent aqueous systems; and composition
WO1989010745A1 (en) * 1988-05-02 1989-11-16 Pomerantz, Edwin Compositions and in situ methods for forming films on body tissue
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンd▲下3▼誘導体含有固形製剤組成物
DK0542926T3 (da) * 1990-08-07 1995-05-15 Pfizer Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
CA2107678A1 (en) * 1991-04-08 1992-10-09 Kouichi Nakamichi Capsule
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
EP0550108B1 (de) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Thyroaktive Zusammensetzung mit kontrollierter Freigabe
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
HU224035B1 (hu) * 1996-05-13 2005-05-30 Novartis Consumer Health S.A. Bukkális adagolórendszer
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US6479082B1 (en) 1996-12-23 2002-11-12 Wm. Wrigley, Jr. Co. Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
AU751117B2 (en) * 1997-11-12 2002-08-08 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 Novel oral dosage form for carvedilol
JP2002532551A (ja) * 1998-12-22 2002-10-02 ノボ ノルディスク アクティーゼルスカブ 新規製剤
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE60037799D1 (de) 1999-04-01 2008-03-06 Wrigley W M Jun Co Strukturen mit langanhaltender geschmacksabgabe fuer kaugummi
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
AU2002221412B2 (en) 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
CN1720026A (zh) * 2002-10-22 2006-01-11 兰贝克赛实验室有限公司 含有阿夫唑嗪的缓释组合物
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
AU2005301046B2 (en) 2004-11-02 2012-02-23 Chr. Hansen A/S Stabilized bacteriophage formulations
KR20080055797A (ko) * 2005-08-23 2008-06-19 닛산 가가쿠 고교 가부시키 가이샤 서방성 제제
EP1959987A2 (de) * 2005-12-08 2008-08-27 Nastech Pharmaceutical Company Inc. Mukosale verabreichung stabilisierter formulierungen aus exendin
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
JP2010518021A (ja) * 2007-01-31 2010-05-27 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ S−アデノシルメチオニンの持続放出医薬製剤
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
KR100836960B1 (ko) * 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
CN102098921A (zh) * 2008-05-19 2011-06-15 温顿制药有限公司 高载量、控释镁口服制剂及其制备和使用方法
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
RU2016117290A (ru) 2012-10-17 2018-10-23 Метилэйшн Сайенсис Интернэшнл Срл Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
CN115429815B (zh) * 2021-06-02 2023-12-22 广州帝奇医药技术有限公司 一种长效饱腹组合物、制备方法及用途
US12239623B2 (en) 2023-05-15 2025-03-04 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3590117A (en) * 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US3876771A (en) * 1973-09-04 1975-04-08 Hallister Inc Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55118414A (en) * 1979-03-05 1980-09-11 Teijin Ltd Prolonged release drug and its preparation
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS58192817A (ja) * 1982-05-06 1983-11-10 Nippon Soda Co Ltd 棒状製剤の製造方法
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
IT8423523A0 (it) 1984-11-09
JPS60185728A (ja) 1985-09-21
NZ210310A (en) 1988-01-08
KR930000046B1 (ko) 1993-01-06
CA1229551A (en) 1987-11-24
DK569784D0 (da) 1984-11-30
AU572571B2 (en) 1988-05-12
NO844280L (no) 1985-06-03
FR2555901B1 (fr) 1988-06-10
GB2152940B (en) 1987-09-03
EG17134A (en) 1991-08-30
DK569784A (da) 1985-06-02
NL193164C (nl) 1999-01-05
SE461071B (sv) 1990-01-08
DK162511C (da) 1992-03-30
MX161165A (es) 1990-08-09
CH664970A5 (de) 1988-04-15
PT79427B (en) 1986-09-15
FR2555901A1 (fr) 1985-06-07
LU85660A1 (de) 1985-06-04
ZA849373B (en) 1985-07-31
HU193717B (en) 1987-11-30
FI844656L (fi) 1985-06-02
NO167002C (no) 1991-09-25
DE3443587C2 (de) 1986-11-06
AU3449984A (en) 1985-06-06
IT8423523A1 (it) 1986-05-09
NL8403522A (nl) 1985-07-01
FI82601C (fi) 1991-04-10
IE58112B1 (en) 1993-07-14
BE901186A (fr) 1985-03-15
KR850004392A (ko) 1985-07-15
PT79427A (en) 1984-11-01
IE843077L (en) 1985-06-01
US4680323A (en) 1987-07-14
IL73594A (en) 1988-12-30
GB8430083D0 (en) 1985-01-09
GB2152940A (en) 1985-08-14
AT394948B (de) 1992-07-27
NO167002B (no) 1991-06-17
IT1177152B (it) 1987-08-26
DK162511B (da) 1991-11-11
FI844656A0 (fi) 1984-11-27
NL193164B (nl) 1998-09-01
SE8406081D0 (sv) 1984-11-30
SE8406081L (sv) 1985-06-02
DE3443587A1 (de) 1985-06-27
HUT35531A (en) 1985-07-29
IL73594A0 (en) 1985-02-28
FI82601B (fi) 1990-12-31

Similar Documents

Publication Publication Date Title
ATA382484A (de) Pharmazeutischer traegerstoff zur dauerabgabe von arzneimitteln mit einem gehalt an celluloseaethern und carboxyvinylpolymer
GB8421347D0 (en) Reverse-phase-control power switching circuits
AU5098085A (en) Power switching device
GB2158313B (en) A switching circuit
GB8429263D0 (en) Load power switching circuits
GB8414855D0 (en) Power switch
DE3271309D1 (en) Switching power supply
GB2168865B (en) Power source circuit
GB2117974B (en) Power switching device
DE3377688D1 (en) Two-mode switching power supply
DE3468593D1 (en) Power transistor
EP0176783A3 (en) Multiple output switching power supply
DE3476307D1 (en) Multiple output switching power supply
GB2149252B (en) Base drive circuit for a power transistor
DE3561433D1 (en) Control circuit for switching a power transistor
EP0219074A3 (en) Two-wire type switch with a power transistor
GB8421070D0 (en) Power switching device
DE3460110D1 (en) Switching power supply with dc input
GB8506258D0 (en) Latched power switching devices
PT79125A (en) A power drive
GB2146932B (en) Power turning device
DE3277672D1 (en) Drive circuit for power switching transistor
AU561286B2 (en) Power transistor switch
GB2180709B (en) A transistor inverter circuit
DE3565349D1 (en) Switching power supply

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee